



AVITA MEDICAL LIMITED (ASX: AVH)

Appendix 3B

Valencia, California, USA, and Melbourne, Australia, 1 August 2019 — Avita Medical Ltd (ASX: AVH) (“AVH” or the “Company”) today announces an Appendix 3B which refers to a number of issues of unlisted options as part of some of its employees’ long-term incentive plans.

AVH advises that the Company inadvertently failed to lodge the required Appendix 3B with the ASX within the prescribed time period. The late lodgement relating to the issues of unlisted options within the attached Appendix 3B arose due to an administrative oversight. The Company has reviewed the oversight and has developed controls and implemented measures to ensure its compliance with ASX Listing Rules.

The Company is committed to compliance with ASX Listing Rules. AVH’s obligations under these rules have now been clarified and, as such, its internal procedures have been amended to ensure future compliance.

###

ABOUT AVITA MEDICAL LIMITED

AVITA Medical is a regenerative medicine company with a technology platform positioned to address unmet medical needs in burns, chronic wounds, and aesthetics indications. AVITA Medical’s patented and proprietary collection and application technology provides innovative treatment solutions derived from the regenerative properties of a patient’s own skin. The medical devices work by preparing a REGENERATIVE EPIDERMAL SUSPENSION™ (RES™), an autologous suspension comprised of the patient’s skin cells necessary to regenerate natural healthy epidermis. This autologous suspension is then sprayed onto the areas of the patient requiring treatment.

AVITA Medical’s first U.S. product, the RECELL® System, was approved by the U.S. Food and Drug Administration (FDA) in September 2018. The RECELL System is indicated for use in the treatment of acute thermal burns in patients 18 years and older. The RECELL System produces Spray-On Skin™ Cells using a small amount of a patient’s own skin, providing a new way to treat severe burns, while significantly reducing the amount of donor skin required. The RECELL System is designed to be used at the point of care alone or in combination with autografts depending on the depth of the burn injury. Compelling data from randomized, controlled clinical trials conducted at major U.S. burn centers and real-world use in more than 7,000 patients globally, reinforce that the RECELL System is a significant advancement over the current standard of care for burn patients and offers benefits in clinical outcomes and cost savings. Healthcare professionals should read the INSTRUCTIONS FOR USE - RECELL® Autologous Cell Harvesting Device for a full description of important safety information including contraindications, warnings and precautions.

In international markets outside of Europe, our products are marketed under the RECELL System brand to promote skin healing in a wide range of applications including burns, chronic wounds and aesthetics. The RECELL System is TGA-registered in Australia, CFDA-cleared in China, and received CE-mark approval in Europe.

To learn more, visit www.avitamedical.com.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This letter includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “intend,” “could,” “may,” “will,” “believe,” “estimate,” “look forward,” “forecast,” “goal,” “target,” “project,” “continue,” “outlook,” “guidance,” “future,” other words of similar meaning and the use of future dates. Forward-looking statements in this letter include, but are not limited to, statements concerning, among other things, our ongoing clinical trials and product development activities, regulatory approval of our products, the potential for future growth in our business, and our ability to achieve our key strategic, operational and financial goal. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Each forward-looking statement contained in this letter is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the timing of regulatory approvals of our products; physician acceptance, endorsement, and use of our products; failure to achieve the anticipated benefits from approval of our products; the effect of regulatory actions; product liability claims; risks associated with international operations and expansion; and other business effects, including the effects of industry, economic or political conditions outside of the company’s control. Investors should not place considerable reliance on the forward-looking statements contained in this letter. Investors are encouraged to read our publicly available filings for a discussion of these and other risks and uncertainties. The forward-looking statements in this letter speak only as of the date of this release, and we undertake no obligation to update or revise any of these statements.

FOR FURTHER INFORMATION:

US Media Sam Brown, Inc Chris Curran Phone +1-615.414.8668 christycurran@sambrown.com O.U.S Media Monsoon Communications Sarah Kemter Phone +61 (0)3 9620 3333 Mobile +61 (0)407 162 530 sarahk@monsoon.com.au	Investors: Westwicke Partners Caroline Corner Phone +1-415-202-5678 caroline.corner@westwicke.com
---	---

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of entity

Avita Medical Ltd

ABN

28 058 466 523

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

1	+Class of +securities issued or to be issued	a) Fully Paid Ordinary Shares b) Unlisted Options
2	Number of +securities issued or to be issued (if known) or maximum number which may be issued	a) 1,524,328 Ordinary Shares b) 23,160,418 Unlisted Options

+ See chapter 19 for defined terms.

- | | |
|---|---|
| <p>3 Principal terms of the +securities (e.g. if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)</p> | <p>a) Same as existing quoted Ordinary Shares</p> <p>b) Unlisted Options to purchase 23,160,418 ordinary shares with the following terms:</p> <ul style="list-style-type: none"> i. 360,000 at an exercise price of \$0.082 per share, with an expiry date of 30 November 2028. ii. 4,910,000 at an exercise price of \$0.082 per share, with an expiry date of 2 January 2029. iii. 380,000 at an exercise price of \$0.089 per share, with an expiry date of 2 January 2029. iv. 6,866,250 at an exercise price of \$0.30 per share, with an expiry date of 1 April 2029. v. 9,644,168 at an exercise price of \$0.42 per share, with an expiry date of 28 June 2029. vi. 1,000,000 at an exercise price of \$0.44 per share, with an expiry date of 1 July 2029. |
| <p>4 Do the +securities rank equally in all respects from the +issue date with an existing +class of quoted +securities?</p> <p>If the additional +securities do not rank equally, please state:</p> <ul style="list-style-type: none"> • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment | <p>a) Yes</p> <p>b) Any shares allocated upon exercise of the Unlisted Options will rank equally with all existing Ordinary Shares from the date of issue.</p> |

5	Issue price or consideration	a) Issued as part of Director share plan, sacrificing cash fee remuneration for receipt of remuneration by way of equity. 1,524,328 shares issued at a number of 10 day VWAPs as follows: i. 58,979 at \$0.393. ii. 163,759 at \$0.139 iii. 263,793 at \$0.085 iv. 268,049 at \$0.084 v. 422,627 at \$0.052 vi. 347,121 at \$0.061 b) Issued as part of employees' long-term incentive plan. Exercise prices as follows: i. 360,000 at an exercise price of \$0.082 per share. ii. 4,910,00 at an exercise price of \$0.082 per share. iii. 380,000 at an exercise price of \$0.089 per share. iv. 6,866,250 at an exercise price of \$0.30 per share. v. 9,644,168 at an exercise price of \$0.42 per share. vi. 1,000,000 at an exercise price of \$0.44 per share.
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	a) Issued as part of Director share plan, sacrificing cash fee remuneration for receipt of remuneration by way of equity. b) Issued as part of employees' long-term incentive plan.
6a	Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b – 6h in relation to the *securities the subject of this Appendix 3B, and comply with section 6i	Yes
6b	The date the security holder resolution under rule 7.1A was passed	30 November 2018
6c	Number of *securities issued without security holder approval under rule 7.1	Nil.

+ See chapter 19 for defined terms.

6d	Number of +securities issued with security holder approval under rule 7.1A	Nil.
6e	Number of +securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	Nil.
6f	Number of +securities issued under an exception in rule 7.2	1,524,328
6g	If +securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the +issue date and both values. Include the source of the VWAP calculation.	Not applicable.
6h	If +securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	Not applicable.
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	Refer to Annexure 1.
7	+Issue dates Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A. Cross reference: item 33 of Appendix 3B.	a) 1,524,328 Ordinary Shares issued on 1 August 2019 b) 23,160,418 Unlisted Options issued on the following dates: i. 360,000 issued on 30 November 2018. ii. 4,910,000 issued on 2 January 2019. iii. 380,000 issued on 2 January 2019. iv. 6,866,250 issued on 1 April 2019. v. 9,644,168 issued on 28 June 2019. vi. 1,000,000 issued on 1 July 2019.

8	Number and ⁺ class of all ⁺ securities quoted on ASX (including the ⁺ securities in section 2 if applicable)	Number	⁺ Class
		1,872,823,903.	Ordinary Shares
9	Number and ⁺ class of all ⁺ securities not quoted on ASX (including the ⁺ securities in section 2 if applicable)	Number	⁺ Class
		114,679,371* 50,000,000	Unlisted Options Unlisted Restricted Stock Units
10	Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)	Not applicable.	

* See Annexure 2

Part 2 - Pro rata issue

11	Is security holder approval required?	Not applicable.
12	Is the issue renounceable or non-renounceable?	Not applicable.
13	Ratio in which the +securities will be offered	Not applicable.
14	+Class of +securities to which the offer relates	Not applicable.
15	+Record date to determine entitlements	Not applicable.
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	Not applicable.
17	Policy for deciding entitlements in relation to fractions	Not applicable.
18	Names of countries in which the entity has security holders who will not be sent new offer documents Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.	Not applicable.
19	Closing date for receipt of acceptances or renunciations	Not applicable.
20	Names of any underwriters	Not applicable.
21	Amount of any underwriting fee or commission	Not applicable.
22	Names of any brokers to the issue	Not applicable.
23	Fee or commission payable to the broker to the issue	Not applicable.

24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	Not applicable.
25	If the issue is contingent on security holders' approval, the date of the meeting	Not applicable.
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	Not applicable.
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	Not applicable.
28	Date rights trading will begin (if applicable)	Not applicable.
29	Date rights trading will end (if applicable)	Not applicable.
30	How do security holders sell their entitlements <i>in full</i> through a broker?	Not applicable.
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	Not applicable.
32	How do security holders dispose of their entitlements (except by sale through a broker)?	Not applicable.
33	⁺ Issue date	Not applicable.

Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

- 34 Type of ⁺securities
(tick one)
- (a) ☒ ⁺Securities described in Part 1

⁺ See chapter 19 for defined terms.

(b) ☐ All other +securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents

- 35 ☐ If the +securities are +equity securities, the names of the 20 largest holders of the additional +securities, and the number and percentage of additional +securities held by those holders
- 36 ☐ If the +securities are +equity securities, a distribution schedule of the additional +securities setting out the number of holders in the categories
- 1 - 1,000
 - 1,001 - 5,000
 - 5,001 - 10,000
 - 10,001 - 100,000
 - 100,001 and over
- 37 ☐ A copy of any trust deed for the additional +securities

Entities that have ticked box 34(b)

- 38 Number of +securities for which +quotation is sought
- 39 +Class of +securities for which quotation is sought
- 40 Do the +securities rank equally in all respects from the +issue date with an existing +class of quoted +securities?
- If the additional +securities do not rank equally, please state:
- the date from which they do
 - the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
 - the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment
-

41 Reason for request for quotation now Example: In the case of restricted securities, end of restriction period (if issued upon conversion of another +security, clearly identify that other +security)	
---	--

	Number	+Class
42 Number and +class of all +securities quoted on ASX (including the +securities in clause 38)		


Quotation agreement

- 1 +Quotation of our additional +securities is in ASX's absolute discretion. ASX may quote the +securities on any conditions it decides.
- 2 We warrant the following to ASX.
 - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those +securities should not be granted +quotation.
 - An offer of the +securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty
 - Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any +securities to be quoted and that no-one has any right to return any +securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the +securities be quoted.
 - If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the +securities be quoted.

+ See chapter 19 for defined terms.

- 3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- 4 We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before +quotation of the +securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.



Sign here:
(Company secretary)

Date: 1 August 2019

Print name: Mark Licciardo

== == == == ==

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1

Rule 7.1 – Issues exceeding 15% of capital	
Step 1: Calculate “A”, the base figure from which the placement capacity is calculated	
Insert number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue	1,342,378,325
Add the following: Number of fully paid +ordinary securities issued in that 12 month period under an exception in rule 7.2	22,061,250 – 11/01/2019 258,799 – 03/04/2019 851,201 – 15/05/2019 300,000 – 21/05/2019 700,000 – 27/05/2019 1,500,000 – 31/05/2019 1,500,000 – 03/06/2019 1,750,000 – 27/06/2019 1,524,328 – 01/08/2019 30,445,578
Number of fully paid +ordinary securities issued in that 12 month period with shareholder approval	186,028,209 – 10/12/2018 124,018,806 – 10/12/2018 189,952,985 – 18/01/2019 500,000,000
Number of partly paid +ordinary securities that became fully paid in that 12 month period	Nil
<i>Note:</i>	

+ See chapter 19 for defined terms.

• <i>Include only ordinary securities here – other classes of equity securities cannot be added</i> • <i>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</i> • <i>It may be useful to set out issues of securities on different dates as separate line items</i>	
Subtract the number of fully paid +ordinary securities cancelled during that 12 month period	Nil
“A”	1,872,823,903

Step 2: Calculate 15% of “A”	
“B”	0.15 <i>[Note: this value cannot be changed]</i>
Multiply “A” by 0.15	280,923,585
Step 3: Calculate “C”, the amount of placement capacity under rule 7.1 that has already been used	
Insert number of +equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued: • Under an exception in rule 7.2 • Under rule 7.1A • With security holder approval under rule 7.1 or rule 7.4 Note: • <i>This applies to equity securities, unless specifically excluded – not just ordinary securities</i> • <i>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</i> • <i>It may be useful to set out issues of securities on different dates as separate line items</i>	Nil
“C”	Nil
Step 4: Subtract “C” from [“A” x “B”] to calculate remaining placement capacity under rule 7.1	
“A” x 0.15 Note: number must be same as shown in Step 2	280,923,585

Subtract “C” <i>Note: number must be same as shown in Step 3</i>	Nil
Total [“A” x 0.15] – “C”	280,923,585 <i>[Note: this is the remaining placement capacity under rule 7.1]</i>

Part 2

Rule 7.1A – Additional placement capacity for eligible entities	
Step 1: Calculate “A”, the base figure from which the placement capacity is calculated	
“A” <i>Note: number must be same as shown in Step 1 of Part 1</i>	1,872,823,903
Step 2: Calculate 10% of “A”	
“D”	0.10 <i>Note: this value cannot be changed</i>
Multiply “A” by 0.10	187,282,390
Step 3: Calculate “E”, the amount of placement capacity under rule 7.1A that has already been used	
Insert number of +equity securities issued or agreed to be issued in that 12 month period under rule 7.1A Notes: • This applies to equity securities – not just ordinary securities • Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed • Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained • It may be useful to set out issues of securities on different dates as separate line items	Nil
“E”	Nil

Step 4: Subtract “E” from [“A” x “D”] to calculate remaining placement capacity under rule 7.1A	
“A” x 0.10 <i>Note: number must be same as shown in Step 2</i>	187,282,390
Subtract “E” <i>Note: number must be same as shown in Step 3</i>	Nil
Total [“A” x 0.10] – “E”	187,282,390 <i>Note: this is the remaining placement capacity under rule 7.1A</i>

AVITA MEDICAL LIMITED (ASX: AVH)
Appendix 3B – Annexure 2

Unlisted Options on Issue as at 30 June 2019

Options Parcel	Exercise Price	Expiration Date
2,156,039	\$0.126	31-Dec-20
16,160,415	\$0.085	18-May-27
1,072,916	\$0.082	26-May-27
1,038,333	\$0.080	27-Jun-27
4,000,000	\$0.063	6-Sep-27
2,000,000	\$0.056	12-Jun-28
3,000,000	\$0.059	25-Jun-28
14,430,000	\$0.089	1-Nov-28
18,881,250	\$0.082	30-Nov-28
3,000,000	\$0.057	18-Apr-28
9,000,000	\$0.057	16-Apr-28
700,000	\$0.057	14-Jun-28
15,000,000	\$0.082	30-Nov-28
1,080,000	\$0.082	2-Jan-29
91,518,953		

Unlisted Options Forfeited (between January and June 2019)

Options Parcel*	Exercise Price	Expiration Date	Forfeited**
17,200,000	\$0.089	1-Nov-28	-2,770,000
24,851,250	\$0.082	30-Nov-28	-5,970,000
1,180,000	\$0.082	2-Jan-29	-100,000
			-8,840,000

* Figure prior to all changes

** Due to hurdle not met or resignation

Unlisted Options issued (between November 2018 and July 2019)

Options Parcel	Exercise Price	Expiration Date	Issued
24,851,250*	\$0.082	30-Nov-28	360,000
1,180,000*	\$0.082	2-Jan-29	4,910,000
380,000**	\$0.089	2-Jan-29	380,000
6,866,250**	\$0.300	1-Apr-29	6,866,250
9,644,168**	\$0.420	28-Jun-29	9,644,168
1,000,000**	\$0.440	1-Jul-29	1,000,000
			23,160,418

* Figure prior to all changes

** New parcel

Unlisted Options on Issue as at 1 August 2019

Options Parcel	Exercise Price	Expiration Date
2,156,039	\$0.126	31-Dec-20
16,160,415	\$0.085	18-May-27
1,072,916	\$0.082	26-May-27
1,038,333	\$0.080	27-Jun-27
4,000,000	\$0.063	6-Sep-27
2,000,000	\$0.056	12-Jun-28
3,000,000	\$0.059	25-Jun-28
14,430,000	\$0.089	1-Nov-28
19,241,250	\$0.082	30-Nov-28
3,000,000	\$0.057	18-Apr-28
9,000,000	\$0.057	16-Apr-28
700,000	\$0.057	14-Jun-28
15,000,000	\$0.082	30-Nov-28
5,990,000	\$0.082	2-Jan-29
380,000	\$0.089	2-Jan-29
6,866,250	\$0.300	1-Apr-29
9,644,168	\$0.420	28-Jun-29
1,000,000	\$0.440	1-Jul-29
114,679,371		

AVITA MEDICAL LIMITED (ASX: AVH)
Cleansing Notice under section 708A of the Corporations Act 2001 (Cth)

Valencia, California, USA, and Melbourne, Australia, 1 August 2019 — Avita Medical Limited (ASX: AVH) (the Company) issued a total of 1,524,328 Fully Paid Ordinary Shares in relation to the share plan approved at the Company's 2016 AGM. The plan allows Directors the option to convert their fees into Avita Medical shares.

The Company gives notice under section 708A(5)(e) of the Corporations Act 2001 (Cth) (Act) in compliance with the requirements of section 708A(6) of the Act as follows:

- (a) The Company issued the shares without disclosure under Part 6D.2 of the Act; and
- (b) As at the date of this notice, the Company has complied with:
 - (i) the provisions of Chapter 2M of the Act as they apply to the Company; and
 - (ii) the provisions of section 674 of the Act.
- (c) The Company is not aware of any information required to be disclosed for the purposes of section 708A(6)(e) of the Act, being information:
 - (i) that has been excluded from a continuous disclosure notice in accordance with the Listing Rules of the ASX; and
 - (ii) that investors and their professional advisors would reasonably require for the purposes of making an informed assessment of:
 - the assets and liabilities, financial position and performance, profits and losses and prospects of the Company; or
 - the rights and liabilities attaching to the Ordinary Shares of the Company.

An Appendix 3B with respect to the issue has been lodged with ASX along with this Cleansing Notice.

As at the date of this Cleansing Notice, there is no excluded information for the purposes of section 708A(7) and section 708A(8) of the Corporations Act.

###

ABOUT AVITA MEDICAL LIMITED

AVITA Medical is a regenerative medicine company with a technology platform positioned to address unmet medical needs in burns, chronic wounds, and aesthetics indications. AVITA Medical's patented and proprietary collection and application technology provides innovative treatment solutions derived from the regenerative properties of a patient's own skin. The medical devices work by preparing a REGENERATIVE EPIDERMAL SUSPENSION™ (RES™), an autologous suspension comprised of the patient's skin cells necessary to regenerate natural healthy epidermis. This autologous suspension is then sprayed onto the areas of the patient requiring treatment.

AVITA Medical's first U.S. product, the RECELL® System, was approved by the U.S. Food and Drug Administration (FDA) in September 2018. The RECELL System is indicated for use in the treatment of acute thermal burns in patients 18 years and older. The RECELL System produces Spray-On Skin™ Cells using a small amount of a patient's own skin, providing a new way to treat severe burns, while significantly reducing the amount of donor skin required. The RECELL System is designed to be used at the point of care alone or in combination with autografts depending on the depth of the burn injury. Compelling data from randomized, controlled clinical trials conducted at major U.S. burn centers and real-world use in more than 7,000 patients globally, reinforce that the RECELL System is a significant advancement over the current standard of care for burn patients and offers benefits in clinical outcomes and cost savings. Healthcare professionals should read the INSTRUCTIONS FOR USE - RECELL® Autologous Cell Harvesting Device for a full description of important safety information including contraindications, warnings and precautions.

In international markets outside of Europe, our products are marketed under the RECELL System brand to promote skin healing in a wide range of applications including burns, chronic wounds and aesthetics. The RECELL System is TGA-registered in Australia, and CFDA-cleared in China.

To learn more, visit www.avitamedical.com.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This letter includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as "anticipate," "expect," "intend," "could," "may," "will," "believe," "estimate," "look forward," "forecast," "goal," "target," "project," "continue," "outlook," "guidance," "future," other words of similar meaning and the use of future dates. Forward-looking statements in this letter include, but are not limited to, statements concerning, among other things, our ongoing clinical trials and product development activities, regulatory approval of our products, the potential for future growth in our business, and our ability to achieve our key strategic, operational and financial goal. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Each forward-looking statement contained in this letter is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the timing of regulatory approvals of our products; physician acceptance, endorsement, and use of our products; failure to achieve the anticipated benefits from approval of our products; the effect of regulatory actions; product liability claims; risks associated with international operations and expansion; and other business effects, including the effects of industry, economic or political conditions outside of the company's control. Investors should not place considerable reliance on the forward-looking statements contained in this letter. Investors are encouraged to read our publicly available filings for a discussion of these and other risks and uncertainties. The forward-looking statements in this letter speak only as of the date of this release, and we undertake no obligation to update or revise any of these statements.

FOR FURTHER INFORMATION:

US Media Sam Brown, Inc Chris Curran Phone +1-615.414.8668 christycurran@sambrown.com O.U.S Media Monsoon Communications Sarah Kemter Phone +61 (0)3 9620 3333 Mobile +61 (0)407 162 530 sarahk@monsoon.com.au	Investors: Westwicke Partners Caroline Corner Phone +1-415-202-5678 caroline.corner@westwicke.com
---	---